More than 100,000 patients worldwide have been prescribed KESIMPTA® (ofatumumab).1 Here are some of them.
The first choice matters. Start with KESIMPTA.
Patient history
Diagnosed in 2022 after experiencing tingling in her hands and numbness in her fingertips
No relapses reported, but her initial MRI scan revealed 5 Gd+ T1 lesions
Karina’s experience with KESIMPTA
Last MRI scan in June 2024 revealed no additional lesions or relapses
After initial medical guidance, had no difficulties self-administering KESIMPTA
Has had a positive experience with KESIMPTA and is optimistic about the future
*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP. Primary end point, ARR reduction of 51% (0.11 vs 0.22), 58% (0.10 vs 0.25).2
Patient history
Diagnosed in 2021 after experiencing numbness in his hand and tingling in his arms
Initial MRI scan revealed lesions on his brain and spine
Andy’s experience with KESIMPTA
He was able to return to work in 2022 after starting KESIMPTA
Likes that treatment doesn’t interfere with his day-to-day activities
Finds that the pen makes it easy to self-administer after initial training
*As per stability technical specification data, when the patient is ready to inject, it typically takes less than 1 minute a month to administer. Once-monthly dosing begins after the initial dosing period, which consists of 20 mg subcutaneous doses at weeks 0, 1, and 2. Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA.2,3
†KESIMPTA Sensoready® Pens must be refrigerated at 2°C to 8°C (36°F to 46°F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30°C (86°F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days.2
Patient history
Diagnosed in 2021 after being diagnosed with optic neuritis
Initial MRI scan revealed 10 Gd+ T1 lesions
Caylee’s experience with KESIMPTA
After her third dose of KESIMPTA, she didn’t experience reactions
As of her last checkup in July 2024, Caylee has shown no new or enlarging lesions and has reported no relapses to date
Patient history
Diagnosed in 2021 after experiencing frequent, painful headaches and a relapse
MRI revealed several lesions
Walt’s experience with KESIMPTA
Feels in control of his RMS and of his life
Sees neurologist regularly and continues his check-ins with the Alongside™ KESIMPTA patient support program
Likes the flexibility and ease of use of at-home administration with an autoinjector
*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP. Primary end point, ARR reduction of 51% (0.11 vs 0.22), 58% (0.10 vs 0.25).2
†As per stability technical specification data, when the patient is ready to inject, it typically takes less than 1 minute a month to administer. Once-monthly dosing begins after the initial dosing period, which consists of 20 mg subcutaneous doses at weeks 0, 1, and 2. Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA.2,3
‡KESIMPTA Sensoready Pens must be refrigerated at 2°C to 8°C (36°F to 46°F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30°C (86°F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days.2
Choose KESIMPTA first for your treatment-naïve RMS patients
These patients switched to KESIMPTA. See why.
Patient history
Proactively discussed a treatment change with her doctor
Diagnosed with RMS at age 20 while filming her hit TV show
Travels frequently with long hours on set
Jamie-Lynn’s experience with KESIMPTA
Treatment has been working for her
Loves being able to self-administer KESIMPTA at home or on set†
Appreciates the hands-on patient support of Alongside KESIMPTA
*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP. Primary end point, ARR reduction of 51% (0.11 vs 0.22), 58% (0.10 vs 0.25).
†KESIMPTA Sensoready Pens must be refrigerated at 2°C to 8°C (36°F to 46°F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30°C (86°F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days.2
Patient history
Diagnosed in 2016 at age 34, after presenting with fatigue, numbness, optic neuritis, relapse
Struggled with compliance on her previous oral DMT
Zenovia’s experience with KESIMPTA
Likes that she can take KESIMPTA once a month at home†
She has not missed a single dose of KESIMPTA
*Based on a cross-sectional survey of adult RMS patients (N=105) in the US who self-administered KESIMPTA with the Sensoready Pen within the previous 12 months. A total of 8 attributes of KESIMPTA Pen use were assessed, including “easy and simple to use,” “easy to prepare,” and “convenient/flexible to travel with.” 89.5% of patients scored a 4 or 5 on characteristics of overall ease of use and ease of monthly dosing schedule. Questionnaire has not been validated. Initiation of KESIMPTA in patients may be influenced by insurance and availability (among other issues). Hence, data should be cautiously interpreted.4,5
†As per stability technical specification data, when the patient is ready to inject, it typically takes less than 1 minute a month to administer. Once-monthly dosing begins after the initial dosing period, which consists of 20 mg subcutaneous doses at weeks 0, 1, and 2. Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA.2,3
Patient history
Diagnosed in 2021, at age 46
Initially presented with joint pain, numbness and tingling, incontinence, and blurred vision
MRI, blood work, and spinal tap confirmed RMS diagnosis
Prescribed a daily oral DMT, but continued to have pain symptoms multiple times a day
Hospitalized during recent relapse
Luis’s experience with KESIMPTA
Continues to take KESIMPTA and follows a healthy lifestyle
Finally feels in control of his RMS, and appreciates not going to a doctor’s office or infusion center for treatment
Patient history
Diagnosed in 2019 after experiencing severe fatigue, loss of the ability to use her left leg, and falling
Her neurologist recommended KESIMPTA after her JC virus index was high on her previous treatment
Brittany’s experience with KESIMPTA
Likes that she can take KESIMPTA once a month at home*
She finds the “second click” feature of the pen to be helpful, reassuring her that she’d administered the medication correctly
*As per stability technical specification data, when the patient is ready to inject, it typically takes less than 1 minute a month to administer. Once-monthly dosing begins after the initial dosing period, which consists of 20 mg subcutaneous doses at weeks 0, 1, and 2. Please see Instructions for Use for more detailed instructions on preparation and administration of KESIMPTA.2,3
Are your patients ready to switch?
ARR, annualized relapse rate; CDP, confirmed disability progression; DMT, disease-modifying therapy; Gd+, gadolinium-enhancing; JC, John Cunningham; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.
References: 1. Data on file. Integrated Dashboard. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2024. 2. Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp. 3. Data on file. Injection time. Novartis Pharmaceuticals Corp; East Hanover, NJ. June 2020. 4. Ross AP, Nicholas J, Tai MH, et al. Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis. LB09. Presented at: Consortium of Multiple Sclerosis Centers Annual Meeting; May 31-June 3, 2023; Aurora, CO. 5. Novartis KESIMPTA Sensoready® pen survey HEORUSV201392. June 2022.